Prospect Therapeutics

Prospect Therapeutics, Inc. is a biopharmaceutical research and development company. Prospect's lead candidate product, GCS-100, is a carbohydrate molecule designed to inhibit the activity of Galectin-3, a protein found in high concentrations in various human cancers, and its overexpression is associated with poor prognosis in cancer patients.